Literature DB >> 31802986

Restarting Biologic Agents After a Drug Holiday.

David T Rubin1.   

Abstract

Year:  2019        PMID： 31802986      PMCID： PMC6883732     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  3 in total

1.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

2.  Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.

Authors:  Filip Baert; David Drobne; Ann Gils; Niels Vande Casteele; Scott Hauenstein; Sharat Singh; Steve Lockton; Paul Rutgeerts; Séverine Vermeire
Journal:  Clin Gastroenterol Hepatol       Date:  2014-01-29       Impact factor: 11.382

3.  Treatment De-Escalation in Patients With Inflammatory Bowel Disease.

Authors:  Amanda Israel; Katia El Jurdi; David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-06
  3 in total
  5 in total

Review 1.  COVID-19 and pediatric inflammatory bowel disease: How to manage it?

Authors:  Roberta Paranhos Fragoso; Maraci Rodrigues
Journal:  Clinics (Sao Paulo)       Date:  2020-06-03       Impact factor: 2.365

2.  Biological and Methotrexate Survival after Pregnancy in Patients With a Rheumatic Disease.

Authors:  Helena Tahmasian; Hieronymus T W Smeele; Pascal H P de Jong; Radboud J E M Dolhain; Elise van Mulligen
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

3.  Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.

Authors:  April Armstrong; Qian Xia; Anand Rojer John; Vardhaman Patel; Lauren Seigel
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-10

Review 4.  Review article: guide to tofacitinib dosing in patients with ulcerative colitis.

Authors:  Peter M Irving; Yvette Leung; Marla C Dubinsky
Journal:  Aliment Pharmacol Ther       Date:  2022-08-22       Impact factor: 9.524

5.  Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.

Authors:  Julian Panés; Séverine Vermeire; Marla C Dubinsky; Edward V Loftus; Nervin Lawendy; Wenjin Wang; Leonardo Salese; Chinyu Su; Irene Modesto; Xiang Guo; Jean-Frederic Colombel
Journal:  J Crohns Colitis       Date:  2021-11-08       Impact factor: 9.071
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.